Sukumar Nagendran - 28 Nov 2025 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: President and Head of R&D, Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Issuer symbol: TSHA
Transactions as of: 28 Nov 2025
Net transactions value: -$1,133,863
Form type: 4
Filing time: 01 Dec 2025, 20:58:44 UTC
Previous filing: 12 Sep 2025
Next filing: 14 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Nagendran Sukumar	President and Head of R&D, Director	C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS	/s/ Kamran Alam, Attorney-in-Fact	01 Dec 2025	0001665124

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TSHA	Common Stock	Options Exercise	$49,043	+70,172	+7%	$0.6989	1,076,611	28 Nov 2025	Direct
transaction	TSHA	Common Stock	Options Exercise	$68,320	+39,953	+3.7%	$1.71	1,116,564	28 Nov 2025	Direct
transaction	TSHA	Common Stock	Sale	$523,094	-110,125	-9.9%	$4.75	1,006,439	28 Nov 2025	Direct	F1
transaction	TSHA	Common Stock	Options Exercise	$444,680	+260,047	+26%	$1.71	1,266,486	01 Dec 2025	Direct
transaction	TSHA	Common Stock	Sale	$1,172,812	-260,047	-21%	$4.51	1,006,439	01 Dec 2025	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Options Exercise	$0	-70,172	-24%	$0.000000	222,683	28 Nov 2025	Common Stock	70,172	$0.6989	Direct	F3
transaction	TSHA	Employee Stock Option (right to buy)	Options Exercise	$0	-39,953	-4.6%	$0.000000	823,664	28 Nov 2025	Common Stock	39,953	$1.71	Direct	F4
transaction	TSHA	Employee Stock Option (right to buy)	Options Exercise	$0	-260,047	-32%	$0.000000	563,617	01 Dec 2025	Common Stock	260,047	$1.71	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
F3	The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
F4	25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.